⏳ Fetching live dividend data...
Home › Calculator › AAPGV Dividend Calculator 2026
Ascentage Pharma Group International · OTC
Price: $17.38 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in AAPGV → $11.46M in 10 years · $107.34/month
Ascentage Pharma Group International is a clinical-stage biotechnology company focused on developing therapeutic solutions for various cancers, chronic hepatitis B virus (HBV) infection, and age-related conditions, primarily within Mainland China. Its flagship product candidate, HQP1351, is a BCR-ABL inhibitor specifically designed to target BCR-ABL1 mutants, notably those harboring the T315I mutation. The company's extensive pipeline further comprises: APG-2575, an orally administered, selective Bcl-2 inhibitor for hematologic malignancies and solid tumors. APG-115, an oral small-molecule inhibitor of MDM2-p53 protein-protein interactions, aimed at treating solid tumors and hematological cancers. APG-1252, a small-molecule drug engineered to restore apoptosis through dual inhibition of Bcl-2 and Bcl-xL proteins, indicated for small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumors, and non-Hodgkin's lymphoma. APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection. APG-2449, an oral inhibitor targeting FAK, ROS1, and ALK kinases. APG-5918, an orally available and selective embryonic ectoderm development inhibitor. APG-265, an MDM2 protein degrader. UBX1967/1325, which are also Bcl-2 inhibitors. Beyond its pharmaceutical development, Ascentage Pharma's operations encompass medical research and development, clinical trial management and execution, venture capital investments, rental services, and the promotion of science and technology. The company cultivates collaborative partnerships with various biotechnology and pharmaceutical enterprises, as well as academic research institutions. Established in 2009, Ascentage Pharma Group International is headquartered in Suzhou, China.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open AAPGV position with:
Real after-tax yield depends on where you live and how you hold AAPGV.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 11.51% | 8.71% | $1,151 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 9.78% | 6.98% | $978 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 9.21% | 6.41% | $921 / yr |
| 🇬🇧 UK ISA | 0% | 11.51% | 8.71% | $1,151 / yr |
| 🇬🇧 UK Taxable | 8.75% | 10.50% | 7.70% | $1,050 / yr |
| 🇨🇦 TFSA | 0% | 11.51% | 8.71% | $1,151 / yr |
| 🇨🇦 CA Taxable | 25% | 8.63% | 5.83% | $863 / yr |
| 🇦🇺 Super (pension) | 15% | 9.78% | 6.98% | $978 / yr |
| 🇦🇺 AU Taxable | 30% | 8.06% | 5.26% | $806 / yr |
| 🇩🇪 DE Taxable | 26.375% | 8.47% | 5.67% | $847 / yr |
| 🇫🇷 FR Taxable | 30% | 8.06% | 5.26% | $806 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
AAPGV pays quarterly — 4 times per year. Next ex-div: TBD.
How AAPGV compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for AAPGV sourced from FMP /financial-growth endpoint — real data, not estimates.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the AAPGV dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Ascentage Pharma Group International (AAPGV) is currently trading at $17.38, trading near its 52-week high. The current dividend yield is 11.51% based on an annual payout of $2.00 per share.
Ascentage Pharma Group International (AAPGV) is a healthcare stock currently trading at $17.38 with a dividend yield of 11.51%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
Auto-generated from live market data. For educational purposes only — not financial advice.
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →If DividendFlow helped you see your future dividend income clearly, other investors deserve the same clarity. Your review takes 30 seconds and makes a real difference.
⏱️ Takes 30 seconds · No signup · Free forever